Ubs Group Ag Pacira Bio Sciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 190,755 shares of PCRX stock, worth $3.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,755

Previous 65,658 190.53%

Holding current value

$3.17 Million

Previous $1.88 Million 52.93%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$11.7 - $28.46 $1.46 Million - $3.56 Million	125,097 Added 190.53%	190,755 $2.87 Million
Q2 2024 Aug 13, 2024	SELL	$25.5 - $31.51 $2.54 Million - $3.14 Million	-99,803 Reduced 60.32%	65,658 $1.88 Million
Q1 2024 May 13, 2024	BUY	$27.7 - $35.48 $1.1 Million - $1.41 Million	39,875 Added 31.75%	165,461 $4.83 Million
Q4 2023 Feb 09, 2024	BUY	$26.32 - $34.31 $1.83 Million - $2.38 Million	69,513 Added 123.97%	125,586 $4.24 Million
Q3 2023 Nov 09, 2023	BUY	$30.68 - $40.09 $972,525 - $1.27 Million	31,699 Added 130.05%	56,073 $1.72 Million
Q2 2023 Aug 11, 2023	SELL	$36.12 - $47.5 $186,993 - $245,907	-5,177 Reduced 17.52%	24,374 $976,000
Q1 2023 May 12, 2023	BUY	$35.53 - $43.38 $76,211 - $93,050	2,145 Added 7.83%	29,551 $1.21 Million
Q4 2022 Feb 08, 2023	BUY	$38.19 - $57.45 $258,278 - $388,534	6,763 Added 32.76%	27,406 $1.06 Million
Q3 2022 Nov 10, 2022	SELL	$51.24 - $58.89 $84,136 - $96,697	-1,642 Reduced 7.37%	20,643 $1.1 Million
Q2 2022 Aug 10, 2022	BUY	$51.49 - $81.64 $39,338 - $62,372	764 Added 3.55%	22,285 $1.3 Million
Q1 2022 May 16, 2022	SELL	$60.03 - $76.49 $121,680 - $155,045	-2,027 Reduced 8.61%	21,521 $1.64 Million
Q4 2021 Feb 14, 2022	SELL	$47.97 - $62.21 $73,538 - $95,367	-1,533 Reduced 6.11%	23,548 $1.42 Million
Q3 2021 Nov 15, 2021	SELL	$54.64 - $61.3 $569,458 - $638,868	-10,422 Reduced 29.36%	25,081 $1.41 Million
Q2 2021 Aug 13, 2021	SELL	$59.18 - $69.99 $739,750 - $874,874	-12,500 Reduced 26.04%	35,503 $2.15 Million
Q1 2021 May 12, 2021	SELL	$59.31 - $78.82 $787,814 - $1.05 Million	-13,283 Reduced 21.67%	48,003 $3.37 Million
Q4 2020 Feb 11, 2021	BUY	$50.47 - $66.26 $1.84 Million - $2.41 Million	36,384 Added 146.11%	61,286 $3.67 Million
Q3 2020 Nov 12, 2020	SELL	$51.97 - $63.0 $702,426 - $851,508	-13,516 Reduced 35.18%	24,902 $1.5 Million
Q2 2020 Jul 31, 2020	SELL	$30.8 - $52.47 $269,962 - $459,899	-8,765 Reduced 18.58%	38,418 $2.02 Million
Q1 2020 May 01, 2020	SELL	$28.4 - $50.7 $781,823 - $1.4 Million	-27,529 Reduced 36.85%	47,183 $1.58 Million
Q4 2019 Feb 14, 2020	BUY	$36.31 - $46.83 $2.07 Million - $2.66 Million	56,874 Added 318.84%	74,712 $3.39 Million
Q3 2019 Nov 14, 2019	SELL	$35.66 - $44.99 $32,093 - $40,491	-900 Reduced 4.8%	17,838 $679,000
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $82,282 - $107,932	2,250 Added 13.65%	18,738 $815,000
Q1 2019 May 14, 2019	BUY	$36.47 - $42.17 $337,858 - $390,662	9,264 Added 128.24%	16,488 $628,000
Q4 2018 Feb 14, 2019	SELL	$41.31 - $52.16 $47,465 - $59,931	-1,149 Reduced 13.72%	7,224 $311,000
Q3 2018 Nov 14, 2018	BUY	$32.85 - $52.0 $20,399 - $32,292	621 Added 8.01%	8,373 $411,000
Q2 2018 Aug 14, 2018	SELL	$27.5 - $39.8 $478,060 - $691,883	-17,384 Reduced 69.16%	7,752 $248,000
Q1 2018 May 15, 2018	SELL	$29.98 - $46.35 $32,978 - $50,985	-1,100 Reduced 4.19%	25,136 $783,000
Q4 2017 Feb 14, 2018	BUY	$31.85 - $46.95 $73,573 - $108,454	2,310 Added 9.65%	26,236 $1.2 Million
Q3 2017 Nov 14, 2017	BUY	$35.7 - $39.5 $218,376 - $241,621	6,117 Added 34.35%	23,926 $899,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,336 Added 23.05%	17,809 $849,000
Q1 2017 Nov 14, 2017	BUY	N/A	14,473	14,473 $660,000

Others Institutions Holding PCRX

# of Institutions

266

Shares Held

50.6M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $761M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account